|
|---|
|
|
|
|
|
w*****d
发帖数: 1172 | | y*****l
发帖数: 5997 | | m*********y
发帖数: 10616 | 3 今天只有CIGX和SUPG值得关注，我觉得大盘已经摇摇晃晃了，暂时不要追涨。 | n********a
发帖数: 1846 | 4 主席AOB还可以跟吗？
【在 m*********y 的大作中提到】
: 今天只有CIGX和SUPG值得关注，我觉得大盘已经摇摇晃晃了，暂时不要追涨。
| n********a
发帖数: 1846 | 5 主席，4.06入了CIGX，不知道怎么样啊，请主席明示
【在 m*********y 的大作中提到】
: 今天只有CIGX和SUPG值得关注，我觉得大盘已经摇摇晃晃了，暂时不要追涨。
| w*****d
发帖数: 1172 | | b******u
发帖数: 1559 | 7 是不是应该补点了？
1.97进的
【在 n********a 的大作中提到】
: 主席AOB还可以跟吗？
| y*****l
发帖数: 5997 | 8 http://finviz.com/screener.ashx?v=341&t=supg CIGX
Two news need study for SUPG before you buy.
SuperGen to Present at Future Leaders in the Biotech Industry on April 15th
http://finance.yahoo.com/news/SuperGen-to-Present-at-Future-bw-
SuperGen agrees to acquire Astex, will change name
SuperGen will buy British drugmaker in cash-and-stock deal, and change name
to Astex Pharma
http://finance.yahoo.com/news/SuperGen-agrees-to-acquire-apf-42
SuperGen to Present at Future Leaders in the Biotech Industry on April 15th
BusinessWireSuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated
to the discovery and development of novel cancer therapies, today announced
that James S.J. Manuso, Ph.D., president and chief executive officer, will
present at Future Leaders in the Biotech Industry 2011 on Friday, April 15th
in New York.
SuperGen's presentation will begin at 9:00 a.m. ET. A live webcast of the
presentation will be available in the Investor Events section of the Company
's website at www.supergen.com. The webcast will be archived for 30 days.
On Thursday April 7, 2011, 1:49 pm EDT
NEW YORK (AP) -- Drugmaker SuperGen Inc. said Thursday it agreed to acquire
British biotechnology Astex Therapeutics Ltd., forming a company called
Astex Pharmaceuticals.
SuperGen, of Dublin, Calif., makes drugs to fight tumors and blood disorders
. It helped develop the drug Dacogen for bone marrow disease. Astex is a
privately held company studying drugs that treat cancer and viruses.
SuperGen said it will acquire Astex for $25 million in cash. Astex
Therapeutics shareholders will own 35 percent of the combined company at
closing, and SuperGen will pay $30 million in additional cash or stock
compensation over a period of 30 months.
Pending approval from shareholders and regulators, the deal is expected to
close in July. If the deal is completed, shares of the combined company will
trade on the Nasdaq under the ticker symbol "ASTX"
SuperGen said the combined company will have seven drug candidates,
including four that are in mid-stage testing or moving into mid-stage
development. Three of those four drugs are being developed through
partnerships with larger drugmakers. Astex Pharmaceuticals will have
partnerships with GlaxoSmithKline PLC, Johnson & Johnson, Novartis AG,
AstraZeneca PLC, and Eisai Co., and it will have revenue from sales of
Dacogen, which is marketed by Johnson & Johnson and Eisai.
The company will be eligible for close to $2 billion in potential drug
development milestone payments.
James Manuso, the president, chairman and CEO of SuperGen, will be chairman
and CEO of the combined company. Astex Therapeutics CEO Harren Jhoti will be
president and a director.
Shares of SuperGen fell 38 cents, or 11.8 percent, to $2.85 in afternoon
trading.
【在 m*********y 的大作中提到】
: 今天只有CIGX和SUPG值得关注，我觉得大盘已经摇摇晃晃了，暂时不要追涨。
|
|
|
|
|
|
|
